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Erasmus MC, Rotterdam, The NetherlandsPeripheral atherosclerotic disease (PAD) occurs com-
monly in the Western Society, with a prevalence of
up to 20% in patients 70 years and older, and is asso-
ciated with an adverse long-term outcome mainly be-
cause of underlying coronary artery disease.1 Patients
at risk for atherosclerotic disease are usually screened
for cardiac risk factors or diseases such as angina pec-
toris, myocardial infarction, and heart failure. It is sur-
prising that a relatively simple, objective and cheap
marker of the extent of atherosclerosis, the ankle-
brachial index (ABI), is not appreciated more fre-
quently by physicians taking care of these patients.
As shownpreviously, theABI correlateswith the extent
of angiographic coronary artery disease, reflecting
the concept that PAD is amarker of generalized athero-
sclerosis.2 As shown in a large cohort study of 3209
patients, both resting and post-exercise ABI values
are strong and independent predictors of long-term
mortality. Risk factors associated with adverse long-
term outcome were the presence of coronary artery
disease (hazard ratio 1.4, 95% CI 1.2e1.6), renal dys-
function (hazard ratio 3.3, 95%CI 2.7e4.2) and smoking
(hazard ratio 1.3, 95%CI 1.1e1.4).3 In the era of pharma-
ceutical interventions targeting blood pressure, lipid
levels, and glucose regulation, the effect of smoking
cessation is often considered too little, while up
to 84% of patients have a history of smoking and
35e40% are current smokers.4,5
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ists ranging from general practitioners, internists, car-
diologists, neurologists and surgeons. The REACH
(REduction of Atherothrombosis for Continued
Health) study is a long-term observational study in-
cluding a wide variety of PAD patients treated by
these specialists. Recently, at the European Society of
Cardiology meeting in Barcelona, the 2-year follow-
up results of the REACH registry were presented.
Importantly, this study addresses the international
differences among patients with PAD. The study
included more than 68,000 patients enrolled from
5,592 sites of 44 countries.6 The registry provides de-
tailed information on risk factors for atherosclerotic
disease, medical therapy, achievement of therapeutic
targets, and long-term outcome among this world-
wide population. As was shown, there is a huge
increase of cardiovascular mortality in patients with
multiple risk factors or manifestations of atheroscle-
rotic disease. Results showed that, during 2-year
follow-up, 20% of patients suffered a major event
or were hospitalized. Similar results were observed
in a large study population from the Netherlands
(Fig. 1). As shown, compared to a matched reference
group for age and gender, patients with symptomatic
PAD had a significantly worse outcome. Importantly,
even when comparing patients with PAD to patients
who underwent percutaneous coronary intervention
(PCI), those with PAD had a worse outcome. One
might speculate about the cause of these observations.
Patients with coronary artery disease are usually
screened and aggressively treated by cardiologists
according to guidelines of the ESC or ACC/AHA.7
Not only pharmaceutical interventions should be
considered, but also, perhaps even more importantly,erved.
716 O. Schouten et al.life-style changes such as smoking cessation. Recently,
van Domburg et al. showed in a consecutive group of
1047 patients with coronary artery disease that pa-
tients who were able to stop smoking were rewarded
with an averaged prolonged gain in life of three years
(van Domburg, personal communication). Impor-
tantly this effect was more pronounced than any other
pharmaceutical intervention.
As stated in the paper by Wilson et al. in the cur-
rent issue of the Journal, awareness of current clinical
guidelines for the treatment of patients with PAD
should be improved among those who provide care
to these patients. Physicians should be aware of the
cardiac risks of their patients with PAD and treat
them accordingly. Not developing new guidelines
for patients with PAD but implementing current
guidelines should be the main focus. Suggestions
to improve the implementation of these guidelines
range from courses for continuous medical training
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Fig. 1. Long-term survival of patients with symptomatic
peripheral atherosclerotic disease, percutaneous coronary
intervention, compared to an age and gender matched
control group.Eur J Vasc Endovasc Surg Vol 33, June 2007to a financial incentive when patients are treated
according to the guidelines. Unfortunately, the most
effective way to implement these guidelines and
improve long term patient’s outcome still remains to
be determined.
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